GlassScriptPhysician profile
Neil J Gilbert
NPI 1053371658
$37,969.47
in general payments reported to CMS, 2019-2025
71 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,299 · 2020: $2,549 · 2021: $3,778 · 2022: $3,951 · 2023: $3,009 · 2024: $4,448 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $8,200 · Travel and Lodging: $1,151 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,873.27 |
| Consulting Fee | $8,200.00 |
| Travel and Lodging | $1,151.04 |
| Education | $168.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $10,288.16 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Amneal Pharmaceuticals LLC | $3,155.50 | 2019-2025 | Crexont, Rytary |
| Ucb, INC. | $2,849.38 | 2019-2025 | Fintepla, Rystiggo, Nayzilam |
| Argenx US, INC. | $1,789.35 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $1,749.84 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,563.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,526.16 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $1,471.09 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $1,078.73 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Emd Serono, INC. | $1,040.12 | 2019-2025 | Mavenclad |
| Pfizer INC. | $810.20 | 2019-2025 | |
| Genzyme Corporation | $725.11 | 2019-2025 | |
| Celgene Corporation | $626.89 | 2021-2025 | Zeposia |
| Vanda Pharmaceuticals INC. | $600.22 | 2020-2025 | Ponvory, Hetlioz |
| Eisai INC. | $590.42 | 2019-2025 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.